MSCs accelerating innovations for BBG

Breaking down acronyms with the experts who work with them day in and day out
April 15, 2019
msc_blog

Anand Srinivasan, Director of Innovation & BioDesign, and Jennifer Wehmeyer, Scientist II, Research & Development, help BioBridge Global and its subsidiaries by working on stem cell research projects, with the goal of getting new ideas into the cellular therapy market. They answer the question “What are MSCs?”

What are MSCs?

MSCs stands for mesenchymal stem cells or mesenchymal stromal cells. These are a type of adult stem cell which possess the ability to form/differentiate into other cells such as skin, bone, fat, cartilage, muscle, tendon and blood vessels.

They are present all over the body, although their concentration is more enriched in some places. Some sources for stem cells include bone marrow, blood, fat tissue, dental pulp and birth tissues.

In addition to differentiation, MSCs can communicate and recruit other cells in their surroundings using chemical signals they secrete (paracrine signaling). MSCs can also modify the immune responses in the human body (immune modulation). This property plays a pivotal role in graft versus host disease, autoimmune diseases etc.

Not every malignancy can be addressed with medication or vaccination. Some aspects of healthcare rely heavily on regenerative medicine and stem cell therapy.

The therapeutic impact of MSCs comes from their use in tissue regeneration and reconstruction, wound healing, immune modulation and cancer treatments . These kinds of treatments are currently being evaluated in animal models and clinical trials.

As MSCs have the ability to differentiate into other cell types, it is important to develop assays and standards that determine the purity of MSCs after large-scale expansion. The role of R&D department is to develop assays that test for the physiological function of MSCs and establish guidelines for safe clinical use.

Within BBG, our business lines work together on sourcing, processing, expansion and testing. This makes us a regenerative medicine enterprise, rightly serving our mission statement of saving and enhancing lives through the healing power of human cells and tissue.


More from our blog:

U.S. needs a safer blood supply, FDA leaders say

Origins of the Blood & Tissue Center Foundation

CTRL meeting needs of cellular therapy industry